Genelux Corporation GNLX
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2023-01-26 |
| Shares Out. | 45,250,000 |
| Website | genelux.com/ ↗ |
| Phone | 18052679889 |
| Employees | 26 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$9.5M |
| Free Cash Flow | -$28.7M |
| Total Assets | $26.2M |
| Total Liabilities | $10.1M |
| Equity | $16.1M |
About Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Genelux Corporation is a publicly traded company under the ticker symbol GNLX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
11 analysts (2026-11-01)